Visual quality assessment of the liver graft by the transplanting surgeon predicts postreperfusion syndrome after liver transplantation: a retrospective cohort study

Table 5 Postoperative outcome

	PRS (n = 65)	no PRS (n = 57)	P
Early allograft dysfunction [n]	25 (38.5%)	16 (28.1%)	0.25
Retransplantation [n]	5 (7.7%)	4 (7.0%)	0.75
Due to primary non function^a [n]	3 (4.6%)	1 (1.8%)
Due to thrombosis [n]	0 (0.0%)	1 (1.8%)
Acute rejection [n]	12 (18.5%)	13 (22.8%)	0.66
Surgical revision [n]	26 (40.0%)	25 (43.9%)	0.72
Bleeding [n]	22 (33.8%)	19 (33.3%)	1.00
Severe infection/sepsis [n]	11 (16.9%)	8 (14.0%)	0.80
Renal function [n]
RRT [n]	27 (41.5%)	20 (35.1%)	0.27
Major cardiovascular events^b [n]	11 (16.9%)	3 (5.3%)	0.05
Adverse CNS events [n]
Delirium [n]	8 (12.3%)	1 (1.8%)	0.04
Intracranial bleeding [n]	3 (4.6%)	0 (0.0%)	0.25
Seizures [n]	1 (1.5%)	1 (1.8%)	1.00
Extubation in the OR [n]	15 (23.1%)	20 (35.1%)	0.16
ICU LOS [days]	11.7 ± 17.0	9.7 ± 15.7	0.09
Hospital LOS [days]	36.5 ± 18.2	35.6 ± 23.9	0.24
Deaths [n]	10 (15.4%)	7 (12.3%)	0.33
Due to sepsis/MOF [n]	6 (9.2%)	6 (10.5%)
Due to cardiovascular events [n]	2 (3.1%)	1 (1.8%)
Due to bleeding [n]	1 (1.5%)	0 (0.0%)
Due to carcinoma [n]	1 (1.5%)	0 (0.0%)

Short-term postoperative outcome of 122 liver transplant recipients with and without postreperfusion syndrome (PRS); RRT renal replacement therapy, CNS central nervous system, ICU intensive care unit; LOS: length of stay MOF multi organ failure PRS postreperfusion syndrome
^aPrimary non-function: re-transplantation or death within 7 days
^bmajor cardiovascular events: asystole, resuscitation, non ST elevation myocardial infarction

ISSN: 1471-2253